Anika Top Line Growth Fueled by Parcus and Arthosurface Acquisitions

Anika Therapeutics reported 1Q20 orthopedic revenue of USD $33.4 million, +45% vs. 1Q19. Continuing purchase orders for MONOVISC and ORTHOVISC offset the near-term impact of procedure deferrals that hampered sales for Parcus and Arthrosurface products. The two recently acquired companies accounted for $6.8 million in revenue for 1Q. Due to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us